Program
Palopegteriparatide
Also written as “TransCon PTH” and “Palopegteriparatide Experimental Arm”.
Its studies are mostly in Hypoparathyroidism, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ascendis Pharma | 21 open or running | phase 3since Jun 23, 2026 | Jun 20, 2019 | Aug 2027phase 3 · NCT07706764 |
| Ascendis Pharma Bone Diseases | 21 open or running | phase 3since Jan 6, 2021 | Jan 6, 2021 | Jun 2027phase 3 · NCT07081997 |
| Visen Pharmaceuticals (Shanghai) | 10 open or running | phase 3since May 18, 2022 | May 18, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 20, 2019First study: phase 2 study in HypoparathyroidismNew to Ascendis PharmaAscendis Pharma · NCT04009291 · 59 enrolled · United States, Canada, Denmark and more
- Jan 6, 2021Ascendis Pharma Bone Diseases’ first study: phase 3 study in HypoparathyroidismNew to Ascendis Pharma Bone DiseasesAscendis Pharma Bone Diseases · NCT04701203 · 84 enrolled · United States, Canada, Denmark and more
- May 18, 2022Visen Pharmaceuticals (Shanghai)’s first study: phase 3 study in HypoparathyroidismNew to Visen Pharmaceuticals (Shanghai)Visen Pharmaceuticals (Shanghai) · NCT05387070 · 81 enrolled · China
- Jul 22, 2025Phase 3 study in HypoparathyroidismAscendis Pharma Bone Diseases · NCT07081997 · 36 planned · United States
- Jun 23, 2026Phase 3 study in HypoparathyroidismPhase 3 reachedAscendis Pharma · NCT07706764 · 12 planned · France, Poland
Ahead
- Jun 2027Primary completion: phase 3 study in HypoparathyroidismAscendis Pharma Bone Diseases · NCT07081997
- Aug 2027Primary completion: phase 3 study in HypoparathyroidismAscendis Pharma · NCT07706764
TargetBeta
“Parathyroid hormone receptor agonist; Parathyroid hormone receptor agonist”ChEMBL 37, by rule
Other programs on PTH1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eneboparatide | AstraZeneca | phase 3 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07706764Hypoparathyroidism · France, Poland | 3 | Recruiting | Ascendis Pharma | Aug 2027 | 12 |
| NCT07081997Hypoparathyroidism · United States | 3 | Recruiting | Ascendis Pharma Bone Diseases | Jun 2027 | 36 |
| NCT05387070Hypoparathyroidism · China | 3 | Completed | Visen Pharmaceuticals (Shanghai) | Jan 4, 2023 | 81 |
| NCT04701203Hypoparathyroidism · United States, Canada, Denmark and more | 3 | Completed | Ascendis Pharma Bone Diseases | Jan 12, 2022 | 84 |
| NCT04009291Hypoparathyroidism · United States, Canada, Denmark and more | 2 | Completed | Ascendis Pharma | Mar 6, 2020 | 59 |
How it is read
Names in the registry
- “TransCon PTH”, 3 entries
- “Palopegteriparatide Experimental Arm”, 1 entry
- “Palopegteriparatide”, 1 entry
Conditions, from the studies’ own filings
- Hypoparathyroidism, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.